| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2016-08-12 |
| タイトル |
|
|
タイトル |
A COMPARISON OF THE EFFICACY AND SAFETY OF TREATMENT WITH SIMEPREVIR AGAINST TELAPREVIR |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
hepatitis C virus |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
interferon |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
ribavirin |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
telaprevir |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
simeprevir |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 作成者 |
ARATA, Suguru
OHSHIMA, Shigetoshi
GOTO, Takashi
MIURA, Kouichi
KOMATSU, Masafumi
NAKANE, Kunio
YAGISAWA, Hitoshi
TAWARAYA, Hironobu
NAKAJIMA, Kou
FUNAOKA, Masato
HOSHINO, Takao
KURAMITSU, Tomoyuki
FUJISHIMA, Yuukou
WATANABE, Daisuke
AJIMINE, Takuma
OHNISHI, Hirohide
|
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
AIM : To compare the efficacy and safety of triple therapy with simeprevir (SMV) against triple therapy with telaprevir (TPV) while treating chronic hepatitis C (CHC). METHOD : A total of 230 CHC patients were enrolled in the present study. One hundred forty-three patients were treated with TPV, and 87 patients were treated with SMV. Univariate analyses were performed to evaluate the pretreatment factors contributing to a sustained virological response at 24 weeks after the end of treatment (SVR24) and adverse events in the TPV and SMV groups. RESULT : The SVR24 rates in the TPV and SMV groups were 81.1% and 76.8%, respectively. The difference was not statistically significant. In the TPV group, the rates of anemia, nausea and renal dysfunction were significantly higher than those in the SMV group. CONCLUSION : In the present study, the SVR24 rates achieved by the two therapies did not differ to a statistically significant extent. However, the rates of some adverse events in the TPV group were significantly higher than those in the SMV group. SMV was associated with low risk and a high SVR24 rate in patients with HCV. |
|
言語 |
en |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 書誌情報 |
ja : 秋田医学
巻 43,
号 1,
p. 29-37,
発行日 2016-06-30
|
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
03866106 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AN00009294 |
| 出版者 |
|
|
出版者 |
秋田医学会 |
|
言語 |
ja |
akitai43-1(29).pdf (839.1 kB)
